The data so far supports the view that IL-1 promotes the anti-cancer efficacy of ingenol mebutate by promoting neutrophil anti-cancer activity, with MyD88 required for IL-1 receptor signal transduction [42]. The gene discussed is IL1A; the disease is cancer.